Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients

Molecular Psychiatry

Volumn 12, Issue 5, 2007, Pages 474-482

  Ruao G ^a   Goethe, J W ^b   Caley, C ^b   Woolley, S ^b   Holford, T R ^c   Kocherla, M ^a   Windemuth, A ^a   Leon, J D ^d  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Eastern State Hospital   (United States)

Author keywords

Antipsychotic agents; Appetite; Lipid metabolism; Obesity; Pharmacogenetics

Indexed keywords

APOLIPOPROTEIN A4; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; LEPTIN RECEPTOR; LIPID; NEUROPEPTIDE Y RECEPTOR; OLANZAPINE; PEPTIDE; RISPERIDONE; SCAVENGER RECEPTOR B;

ADULT; AGED; APPETITE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; FEMALE; FOOD INTAKE; GENETIC ASSOCIATION; GENETICS; GENOMICS; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEINS; APPETITE REGULATION; ARYLDIALKYLPHOSPHATASE; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FEMALE; GENOMICS; HUMANS; LIPID METABOLISM; MALE; MENTAL DISORDERS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; RECEPTORS, NEUROPEPTIDE Y; RISPERIDONE; SCAVENGER RECEPTORS, CLASS B; WEIGHT GAIN;

EID: 34247481499     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001944     Document Type: Article

References (67)

1. Muller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329.
2. Correll CU, Malhotra AK. Pharmacogenetics of antipsychoticinduced weight gain. Psychopharmacology 2004; 174: 477-489.
3. Ruaño G, Zöllner S, Goethe JW. Drug-induced metabolic syndrome (DIMS) in psychiatry: a diagnostic need uniquely suited to pharmacogenomics. In: Wong SHY, Linder MW, Valdes Jr R (eds). Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine. AACC Press: Washington, DC, 2006, pp 277-282.
4. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374.
5. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-566.
6. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population-based nested case-control study. BMJ 2002; 325: 243.
7. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920-930.
8. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002; 63: 758-762.
9. Linnet K. Glucuronidation by cDNA-expressed human UDP- glucuronyltransferases and human liver microsomes. Hum Psychopharmacol 2002; 17: 233-238.
10. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics Part I: pharmacology, pharmacokinetics and efficacy. Ann Pharmacother 1999; 33: 73-85.
11. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57(Suppl 11): 12-25.
12. Ganguli R, Brar JS, Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr Res 2001; 49: 261-267.
13. Bork J, Rogers T, Wedlund P, de Leon J. A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469-476.
14. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72.
15. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149: 689-690.
16. Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J. The relationship of changes in leptin, neuropeptide Y and reproductive hormone to antipsychotic-induced weight gain. Hum Psychopharmacol Clin Exp 2003; 18: 551-557.
17. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 68(Suppl 1): S60-S64.
18. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
19. Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J Clin Psychiatry 2006; 67: 1473-1474.
20. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224-235.
21. Basile VS, Masellis M, McIntyre RS, Ozdemir V, Meltzer HY, Macciardi FM et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
22. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003; 23(Suppl 1): S21-S26.
23. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363.
24. Ruaño G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005; 6: 865-872.
25. Ruaño G, Windemuth A, Kocherla M, Holford T, Fernandez ML, Forsythe CE et al. Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction. Nutr Met 2006; 3: 20-30.
26. Ruaño G, Windemuth A, Holford TR. Physiogenomics: Integrating systems engineering and nanotechnology for personalized medicine. In: Bronzino JD (ed). The Biomedical Engineering Handbook, 3rd edn. CRC Press: Boca Raton, FL, 2005, pp 281-289.
27. Saltelli A, Chan K, Scott EM. Sensitivity Analysis. John Wiley and Sons: Chichester, 2000.
28. Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 2005; 46: 1888-1895.
29. Eckhardt ER, Cai L, Sun B, Webb NR, van der Westhuyzen DR. High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem 2004; 279: 14372-14381.
30. Kalra SP, Kalra PS. NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy (review). Neuropeptides 2004; 38: 201-211.
31. de Leon J, Susce MT, Pan RM, Fairchild M, Koch W, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27.
32. Oliphant A, Barker DL, Stuelpnagel JR, Chee MS. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques 2002; 32: S56-S61.
33. Fan JB, Oliphant A, Shen R, Kermani B, Garcia F, Gunderson KL et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003; 68: 69-78.
34. R Development Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2004; http://www.R-project.org.
35. Dalgaard P. Introductory Statistics with R. Springer: New York, 2002.
36. Maindonald J, Braun J. Data Analysis and Graphics Using R. Cambridge University Press: Cambridge, 2003.
37. Faraway JJ. Linear Models with R. Chapman & Hall/CRC: Boca Raton, FL, 2004.
38. Reinere A, Yekutiele D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-375.
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Series B 1995; 57: 289-300.
40. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Educ Behav Stat, 2000; 25: 60-83.
41. Rosner B. Fundamentals of Biostatistics, 4th edn. Duxbury Press: Belmont, 1995.
42. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 829-836.
43. Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 1988; 83: 596-610.
44. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci USA 2004; 101: 4531-4536.
45. Liu Y-J, Rocha-Sanchez SM, Liu PY, Long J-R, Lu Y, Elze L et al. Tests of linkage and/or association of the LEPR gene polymorphisms with obesity phenotypes in Caucasian nuclear families. Physiol Genomics 2004; 17: 101-106.
46. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 2001; 108: 233-236.
47. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA Polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62: 36-44.
48. Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, Baldwin CT, et al., MIRAGE Study Group. Polymorphisms in the PON gene cluster are associated with Alzheimer's disease. Hum Mol Genet 2006; 15: 77-85.
49. Blumenthal JB, Andersen RE, Mitchell BD, Seibert MJ, Yang H, Herzog H et al. Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride and high-density lipoprotein cholesterol levels. Clin Genet 2002; 62: 196-202.
50. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by ApoE phenotype: a meta-analysis. J Lipid Res 1992; 33: 447-454.
51. Rubinsztein DC, Easton DF. Apolipoprotein E genetic variation and Alzheimer's disease: a meta-analysis. Dement Geriatr Cogn Disord 1999; 10: 199-209.
52. Vanhanen M, Kivipelto M, Koivisto K, Kuusisto J, Mykkanen L, Helkala EL et al. APOE-Epsilon4 is associated with weight loss in women with AD: a population-based study. Neurology 2001; 56: 655-659.
53. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
54. American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), American Psychiatric Association (APA), North American Association for the Study of Obesity (NAASO). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
55. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200.
56. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 76-78.
57. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC et al.Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 394-397.
58. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26: 128-134.
59. Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004; 9: 1067-1074.
60. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
61. Buckley PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001; 50: 912-924.
62. Olfson M, Blanco C, Liu L, Moreno C, Laje G. Mutational trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-685.
63. Ruaño G. Quo Vadis personalized medicine? Personalized Med 2004; 1: 1-7.
64. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796.
65. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001; 1: 3-10.
66. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24: 75-85.
67. Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 2006; 7: 119-133.